Two different protein expression profiles of oral squamous cell carcinoma analyzed by immunoprecipitation high-performance liquid chromatography

Soung Min Kim 1, Dasul Jeong 2, Min Keun Kim 3, Sang Shin Lee 2 and Suk Keun Lee 2*

Abstract

Background: Oral squamous cell carcinoma (OSCC) is one of the most dangerous cancers in the body, producing serious complications with individual behaviors. Many different pathogenetic factors are involved in the carcinogenesis of OSCC. Cancer cells derived from oral keratinocytes can produce different carcinogenic signaling pathways through differences in protein expression, but their protein expression profiles cannot be easily explored with ordinary detection methods.

Methods: The present study compared the protein expression profiles between two different types of OSCCs, which were analyzed through immunoprecipitation high-performance liquid chromatography (IP-HPLC).

Results: Two types of squamous cell carcinoma (SCC) occurred in a mandibular (SCC-1) and maxillary gingiva (SCC-2), but their clinical features and progression were quite different from each other. SCC-1 showed a large gingival ulceration with severe halitosis and extensive bony destruction, while SCC-2 showed a relatively small papillary gingival swelling but rapidly grew to form a large submucosal mass, followed by early cervical lymph node metastasis. In the histological observation, SCC-1 was relatively well differentiated with a severe inflammatory reaction, while SCC-2 showed severely infiltrative growth of each cancer islets accompanied with a mild inflammatory reaction. IP-HPLC analysis revealed contrary protein expression profiles analyzed by 72 different oncogenic proteins. SCC-1 showed more cellular apoptosis and invasive growth than SCC-2 through increased expression of caspases, MMPs, p53 signaling, FAS signaling, TGF-β1 signaling, and angiogenesis factors, while SCC-2 showed more cellular growth and survival than SCC-1 through the increased expression of proliferating factors, RAS signaling, eIF5A signaling, WNT signaling, and survivin.

Conclusions: The increased trends of cellular apoptosis and invasiveness in the protein expression profiles of SCC-1 were implicative of its extensive gingival ulceration and bony destruction, while the increased trends of cellular proliferation and survival in the protein profile of SCC-2 were implicative of its rapid growing tumor mass and early lymph node metastasis. These analyses of the essential oncogenic protein expression profiles in OSCC provide important information for genetic counseling or customized gene therapy in cancer treatment. Therefore, protein expression profile analysis through IP-HPLC is helpful not only for the molecular genetic diagnosis of cancer but also in identifying target molecules for customized gene therapy in near future.

Keywords: Protein expression profile, Oral squamous cell carcinoma (OSCC), Immunoprecipitation high-performance liquid chromatography (IP-HPLC), Potential target gene

* Correspondence: sukkeunlee@hanmail.net

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Squamous cell carcinoma (SCC) is the most frequent and serious malignant tumor in the oral cavity. Although it can be easily recognized by patients themselves or detectable through simple clinical observation, the surgical removal of a SCC lesion is still difficult due to complicated anatomical structures in the oral and maxillofacial region composed of neuromuscular and dento-skeletal tissues [1, 2]. Therefore, the combination treatment of surgery, radiation, and chemotherapy is frequently recommended following a pathological diagnosis. Surgical therapy is the immediate and primary treatment to eradicate the cancer tissue, and radiation therapy and chemotherapy have been developed to induce cellular apoptosis and arrest the growth of cancer cells [3–5].

Many cases of oral squamous cell carcinoma (OSCC) recur even after radical excision of the tumor lesion, leading to a poor prognosis. Radiation therapy and chemotherapy are also sometimes ineffective on target cancer cells depending on their oncogenic status in terms of cellular differentiation, proliferation, apoptosis, survival, migration, and other factors. In order to properly treat OSCCs, pathological examination should be carefully performed along with a molecular biological investigation to determine the final diagnosis. Therefore, it is critical to determine the cellular biological status of cancer cells, which could be identified by their protein expression profiles for different oncogenic signaling pathways [6, 7]. The present study was performed to explore the molecular biological dynamics in two different types of OSCCs through analysis with immunoprecipitation high-performance liquid chromatography (IP-HPLC).

The two OSCCs showed different histological features in cancer growth and propagation and had contrary protein expression profiles implicative of their differences in carcinogenesis progression. Fortunately, a sufficient amount of protein extract was obtained from both cases of OSCCs during surgical excision of the tumor mass followed by selective neck dissection. Each protein extract was analyzed through IP-HPLC methods, which have been much improved in data accuracy and statistical analysis. These results are discussed along with a review of the literature.

Methods

Two representative OSCCs were selected from the files of the Department of Oral Pathology, Gangneung-Wonju National University Dental Hospital (GWNUDH) under the approval of institutional review board (IRB2016–11). Both cases occurred in a mandibular molar (SCC-1) and posterior maxillary area (SCC-2) in male patients who were 65 and 69 years old. However, their clinical/radiological features and pathological diagnosis were somewhat different, as was their subsequent prognosis.

Patients data

SCC-1 case showed more extensive bony destruction around the mandibular molar area involving the upper half of the mandibular body. The patient is a 65-year-old man with large gingival ulceration with severe halitosis on the lower left gingiva, 4 × 6 cm sized with extensive buccal cortex bony invasion. It was diagnosed as a squamous cell carcinoma with stage IV, thus partial mandibulectomy with functional neck dissection with level I to III, reconstruction with an R-plate and radial forearm free flap. Post-operative radiotherapy with 7200 Gray, and no recurrence or metastasis during 3 years and 6 months’ follow-up period (Fig. 1, Table 1).

SCC-2 case showed localized bony destruction around the left maxillary posterior gingiva and early tumor metastasis to the cervical lymph nodes. The patient was a 69-year-old man with a relatively small papillary gingival swelling mass on the left upper posterior gingiva. This lesion grew rapidly to form a 4 × 6 cm sized submucosal mass and was diagnosed as a squamous cell carcinoma with stage III. Extended maxillectomy with functional neck dissection of level I to III combined with buccal fat graft were operated. Although post-operative radiotherapy with 6500 Gray was executed, there was cervical node metastases during 4 years’ follow-up period (Fig. 1, Table 1). Unfortunately, the patient is not followed-up anymore.

Histological and immunohistochemical staining

The surgically removed specimens were fixed in 10% neutral buffered formalin, processed routinely, and embedded in paraffin. Histologic sections with a thickness of 4 μm were mounted on glass slides and stained with hematoxylin and eosin. Serial micro-sections were also prepared for immunohistochemical staining using the different antisera listed in Table 2. The immunohistochemical reaction protocols used for this study differed according to the target antigen and manufacturers’ protocols. Briefly, after deparaffinization and rehydration of the tissue sections in xylene followed by ethanol, sections were incubated with 0.5% hydrogen peroxide in phosphate-buffered saline for 30 min. Primary anti-human (rabbit/mouse/goat) polyclonal antibodies were applied to each micro-section using the triple sandwich indirect immunohistochemical method [8]. Microscopic images were captured by a digital camera (DP-70*, Olympus Co., Japan), followed by statistical analysis using the image analysis program (IMT i-Solution*, ver 21.1, Vancouver, Canada).

IP-HPLC analysis for the protein extract obtained from RAW 264.7 cell culture

One hundred microgram of each protein extract was applied to the immunoprecipitation procedure using a
protein A/G agarose column (Amicogen Co., Korea). The protein A/G agarose columns were separately pre-incubated with 1 μg of each of the 25 different antisera, including β-actin, Ki-67, PCNA, MAX, cMyc, E2F-1, Rb-1, and MAD (Santa Cruz Biotech, USA). Briefly, the protein samples were mixed with 5 mL of binding buffer (150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium vanadate, 0.2 mM PMSF, and 0.5% NP-40) and incubated in the protein A/G agarose columns at 10 °C for 1 h. The columns were placed on a rotating stirrer during the incubation. After washing each column with a sufficient amount of PBS solution (pH 7.3, 137 mM NaCl, 2.7 mM KCl, 43 mM Na₂HPO₄-7H₂O, and 1.4 mM KH₂PO₄), the target protein was eluted with 150 μL of IgG elution buffer (Pierce Co., USA). The immunoprecipitated proteins were analyzed by HPLC (1100 series®, Agilent, USA) using a reverse phase column and micro-analytical detector system (SG Hightech Co., Korea), operated with a 0.15 M NaCl, 20% acetonitrile solution at 0.4 mL/min for 30 min, and analyzed by UV spectroscopy at 280 nm. IP-HPLC analysis was performed simultaneously for both the control and experimental groups.

In the IP-HPLC results, the sample protein peak areas (mAU*s) obtained from HPLC analysis in the negative control were used to eliminate the antibody peak area (mAU*s) [9, 10]. To compare the two different types of SCCs, the protein peak area values of SSC-1 and SSC-2 were proportionally normalized by the α-tubulin value and plotted as a bar and radial line graph.

**Results**

**Histological and immunohistochemical findings**

Histologically, SSC-1 was diagnosed as a well differentiated SCC forming many cancer pearls (Fig. 2 A1-A2), and SSC-2 was diagnosed as a poorly differentiated OSCC exhibiting numerous infiltrating tumor islets into the underlying connective tissue (Fig. 2 B1-B2).

In the immunohistochemical staining, the SCC-1 tumor cells were strongly positive for p53 (Fig. 2 A3), TGF-β1, c-erbB2, caspase-9, PARP, FAS, FASL, MMP-2, and MMP-9, while the SCC-2 tumor cells were strongly positive for KRAS (Fig. 2 B3), STAT3, MPM2, elf5A, DHS, DOHH, snail, and survivin (data not shown).

**IP-HPLC analysis from SCC-1 and SCC-2**

The IP-HPLC analysis revealed that SCC-1 showed more cellular transformation and apoptosis than SCC-2, while SSC-2 showed more invasive growth and cellular survival than SCC-1 (Figs. 3 and 4). In the protein expression profile of SCC-1, the neoplastic proliferation of tumor cells was supported by the overexpression of E2F-1 and c-erbB2, and the cellular transformation and differentiation of tumor cells were related to the overexpression of TGF-β1, TGase-1, HO-1, hTERT, and p38 compared to SCC-2. Particularly, SCC-1 showed overexpression of apoptosis-related proteins, e.g., p53, BAD, BAK, BID, BCL2, FAS, FASL, FLIP, caspase-3, caspase-8, caspase-9, and PARP compared to SSC-2, indicating that the oncogenic progression in SCC-1 was related to the activation of p53 and FAS signaling compared to SCC-2 (Fig. 3).

On the other hand, in the protein expression profile of SCC-2, the neoplastic proliferation of the tumor cells was related to the overexpression of PCNA, MPM2, KRAS, STAT3, EGFR, and bFGF and supported by the overexpression of protein translation factors, e.g., elf5A, DHS, and DOHH, compared to SCC-1. The p53 expression was partly suppressed by the overexpression of MDM2, followed by the compensatory overexpression of p16 and p21. The oncogenic progression was relevant to

**Table 1 Clinical courses of SCC-1 and SCC-2**

| Patient | Age | Sex | Size (cm) | Location | Stage | Adjuvant therapy | Operation | Follow-up | Recurrence |
|---------|-----|-----|-----------|----------|-------|-----------------|-----------|-----------|------------|
| SCC-1   | 65  | M   | 4 × 6     | Lt Mn    | pT4N0M0 | PORT            | Partial mandibulectomy, SOHND, R-plate with RFFF reconstruction | 3 years and 6 months | None       |
| SCC-2   | 69  | M   | 2 × 3     | Lt Mx    | pT3aN0M0| PORT            | Extended maxillectomy, SOHND, local flap with buccal fat graft | 4 years | Neck metastasis |

SCC squamous cell carcinoma, Lt left, Mx maxilla, Mn mandible, PORT post-operative radiation therapy, SOHND supraomohyoid neck dissection, RFFF radial forearm free flap
the activation of RAS and WNT signaling proteins, e.g., KRAS, STAT3, WNT1, β-catenin, snail, and PTCH, compared to SSC-1. The tumor cells also showed increased cellular survival by the overexpression of survivin, HSP-70, 14–3–3, and angiogenesis-related proteins, e.g., HIF, vWF, CMG2, and bFGF, compared to SSC-1 (Fig. 3).

The radial line graph shown in Fig. 4 clearly demonstrates the differences in essential protein expression profiles between SSC-1 and SSC-2. The protein expression of SSC-1 was shifted into the abortive cycles of cellular differentiation, transformation, and apoptosis, while the protein expression of SSC-2 was shifted into the abortive cycles of oncogenic cellular growth and survival (Fig. 4). These findings indicate that the carcinogenesis progression processes of the two SCCs are different even though they are both derived from keratinocytes of the oral mucosa.

**Discussion**

The present study investigated the protein expression profiles of two representative types of OSCCs. Although these data were obtained from preliminary analysis in a series of OSCC research, the recent strategy of molecular biological gene therapy urgently recommends the collection of oncogenic signaling data from cancer cells in each individual patient. Therefore, our study utilized IP-HPLC analysis, which has been designed to perform quantitative protein analysis using different but comparable protein samples.

During the past several years, liquid chromatography tandem mass spectrometry (LC-MS/MS) has emerged as an innovative analytical technology applicable to wide ranges of sample's molecules. Mass spectrometry (MS) is an analytical technique that ionizes chemical species and sorts the ions based on their mass-to-charge ratio, and the mass spectrum is a plot of the ion signal as a function of the mass-to-charge ratio. These spectra are used to determine the elemental or isotopic signature of a sample, and to elucidate the chemical structures of molecules, such as peptides and other chemical compounds [11]. MS has increased in speed, accuracy and use, and with the ability of the mass spectrometers to identify increasing numbers of proteins, the identification of undesirable peptides has also increased [12]. Because the IP-HPLC analysis is based on the antibody interaction with target protein which may be specific and sensitive depending on the epitope binding activity of antibody, it has to utilize mathematical calculation for the relative protein quantitation compared to the control. Therefore, it is thought that the data obtained from IP-HPLC analysis may be quite different from those from mass spectrometry (MS-MS) which is able to provide the absolute quantitation of proteins.

The histological differences between SSC-1 and SSC-2 were characterized by the dominant carcinogenic features of cellular proliferation, apoptosis, invasion, and survival.

### Table 2 Antibodies used in this study

| Signaling proteins | Number | Antibodies |
|--------------------|--------|------------|
| Cytoskeletal proteins | 1 | α-Tubulin |
| Growth factor-related proteins | 5 | EGFR, c-erbB2, TGF-β1, bFGF, HGF |
| Proliferation-related proteins | 9 | eIF5A1, DHS, DOHH, PCNA, MPM-2, CDK4, c-Myc, Max, hTERT |
| Transcription signaling proteins | 3 | NFκB, p38, E2F-1 |
| Apoptosis-related proteins | 14 | FAS, Fasl, PARP, BAX, NOXA, PUMA, BAD, BAK, Bid, caspase 3, caspase 8, caspase 9, FADD, FLIP |
| Cell survival-related proteins | 3 | pAKT, MDM2, BCL2 |
| Tumor suppressor proteins | 8 | p16, p21, p53, p63, RB1, PTEN, PTPN11, NF1 |
| Oncoproteins | 9 | 14–3–3-σ, CEA, STAT3, survivin, DMBT1, maxpax, snail, KRAS, PIM1 |
| Protection proteins | 5 | HO-1, caveolin, HSP-70, FAK, TGase-1 |
| Proinflammation proteins | 2 | TNFα, SHP-1 |
| WNT/β-catenin pathway proteins | 4 | SHH, β-catenin, WNT1, APC |
| Matix proteolysis proteins | 4 | MMP-1, MMP-2, MMP-9, elastin |
| Angiogenesis-related proteins | 5 | HIF-1α, VEGF, vWF, angiogenin, CMG2 |
| Total | 72 | |

Abbreviation: pAKT v-akt murine thymoma viral oncogene homolog (phosphorylated at Thr 308), APC adenomatous polyposis coli, BAD BCL2 associated death promoter, BAX BCL2 antagonist/killer, BAX-BCL2 associated X, BCL-2 B-cell leukemia/lymphoma-2, BID BHS interacting-domain death agonist, CDK4 cyclin dependent kinase 4, CEA carcinoembryonic antigen, CMG2 capillary morphogenesis protein 2, DHS deoxycytidine synthase, DOHH deoxyhypusine hydroxylase, DMBT1 deleted in malignant brain tumor, E2F-1 transcription factor, EGFR epidermal growth factor receptor, eIF5A eukaryotic translation initiation factor 5A, FADD FAS associated via death domain, FAK focal adhesion kinase, FAS CD95/Apo1, FASL FAS ligand, bFGF basic fibroblast growth factor, FLIP FAS-like inhibitory protein, HGF hepatocyte growth factor, HIF hypoxia inducible factor, HO-1 heme oxygenase 1, HSP-70 heat shock protein 70, KRAS V-KI-ras Kirsten rat sarcoma viral oncogene homolog, MAX myc-associated factor X, MDM2 mouse double minute 2 homolog, MMP-1 matrix metalloproteinase-1, MMP-2 mitotic protein monoclonal 2, MHC myc-like myelocytomatosis viral oncogene homolog (avian), NF-1 neurofibromin-1, NFκB nuclear factor kappa-light-chain-enhancer of activated B cells, NOXA phorbol-12-myristate-13-acetate-induced protein 1, PARP p53 up-regulated modulator of apoptosis, PTPN11 retinoblastoma 1, SHH sonic hedgehog, SHP-1 short helical protein-1, SOCS-1 Son of sevenless-1, PTEN phosphatase and tensin homolog, PUMA p53 up-regulated modulator of apoptosis, RBT1 retinoblastoma 1, SHH sonic hedgehog, SHP-1 short helical protein-1, SOCS-1 Son of sevenless-1, STATS signal transducer and activator of transcription-3, hTERT human telomerase reverse transcriptase, TGF-β transforming growth factor-β1, TGase-1 transglutaminase-1, TGF-β1 transforming growth factor-β1, TNFα tumor necrosis factor-α, VEGF vascular endothelial growth factor, vWF von Willebrand factor |

SANTA CRUZ BIO TECHNOLOGY, USA

DAKO, Denmark

Neomarkers, CA, USA

ZYMED, CA, USA
which were related to differences in oncogenic signaling in cancer cells. In the immunohistochemical staining, the tumor cells of SSC-1 were strongly positive for p53, TGF-β1, c-erbB2, caspase-9, PARP, FAS, FASL, MMP-2, and MMP-9, while the tumor cells of SSC-2 were strongly positive for KRAS, STAT3, MPM2, eIF5A, DHS, DOHH, snail, and survivin. These findings were similar to many previous reports [13–18] illustrating how oncogenic signaling functions in cancer cells, although their expression levels were not quantitative but derived from the intensity of peroxidase reaction with the chromogens 3,3′-diaminobenzidine (DAB) or 3-amino-9-ethylcarbazole (AEC). Therefore, a more precise detection system should be applied in the investigation of protein expression for molecular signaling as in this study.

The present IP-HPLC analysis disclosed that the neoplastic proliferation of SCC-1 was related to the overexpression of E2F-1 and c-erbB2, and the cellular transformation and differentiation of SCC-1 was related to the overexpression of TGF-β1, TGase-1, HO-1, hTERT, and p38 compared to SSC-2. Particularly, SCC-1 showed the overexpression of apoptosis-related proteins, e.g., p53, BAD, BAK, BID, BCL2, FAS, FASL, FLIP, caspase-3, caspase-8, caspase-9, and PARP, compared to SCC-2, indicating that oncogenic progression in SSC-1 is related to the activation of p53 and FAS signaling or cellular apoptosis compared to SCC-2. Thus, oncogenic signaling could progress from multiple pathways involved in cellular proliferation, differentiation, apoptosis, and survival in cancer cells, and these results were similar to those of previous reports [19–21].

On the other hand, in the protein expression profile of SSC-2, the neoplastic proliferation of tumor cells was related to the overexpression of PCNA, MPM2, KRAS,
STAT3, EGFR, and bFGF and was supported by the overexpression of the protein translation factors eIF5A, DHS, and DOHH compared to SSC-1. Therefore, it was presumed that the major oncogenic signaling of SSC-2 was derived from RAS signaling supported by different growth factors and active protein translation [22–24].

The p53 expression in SSC-2 was partly suppressed by the overexpression of MDM2, followed by the compensatory overexpression of p16 and p21; thereby, the major tumor suppressor protein p53 might be down-regulated and compensated by other cell cycle inhibitors in SCC-2. Through comparison of the protein expression profiles of SCC-1 and SCC-2, the oncogenic progression of SCC-2 was assumed to be related to activation of the RAS and WNT signaling proteins, e.g., KRAS, STAT3, WNT1, β-catenin, snail, and PTCH, compared to SCC-1 [25]. Therefore, the propagation of SSC-2 was more aggressive with early cervical lymph node metastasis and rapid recurrence compared to SCC-1 even after radical surgery.

The tumor cells of SCC-2 also showed increased cellular survival by the overexpression of survivin [26], HSP-70, 14-3-3, and the angiogenesis-related proteins HIF, vWF, CMG2, and bFGF compared to SCC-1 [27]. It was presumed that cellular protection, survival, and angiogenesis are closely associated with each other and support or compensate their molecular signaling, resulting in propagation of cancer cells. Therefore, these signaling pathways could be oncogenic for SCC as well as potentially important proteins for targeting by anti-cancer drugs.

The radial line graph (Fig. 4) clearly demonstrates the differences in essential protein expression profiles between SSC-1 and SCC-2. The protein expression of SCC-1 was shifted into the abortive cycles of cellular differentiation, transformation, and apoptosis, while the protein expression of SSC-2 showed more invasive growth and cellular survival than SCC-1 by the overexpression of proliferating factors, RAS signaling, eIF5A signaling, Wnt signaling, and survivin.

As cellular apoptosis was dominant in the oncogenic signaling of SCC-1 with the overexpression of p53, it is suggested that SCC-1 could be effectively treated by radiation therapy, which can induce severe DNA damage followed by cellular apoptosis. For SCC-2, which showed...
dominant expression of RAS and WNT signaling, it is suggested to treat with multiple drugs targeting the RAS and WNT pathways and related proteins. For the “apoptosis-related proteins” in Table 2, the regulation of apoptosis and cell proliferation by oncogenes, tumor-suppressor genes and growth factors in OSCC was already well known in many previous published articles [28–30]. About the p53, TNF, and Fas signaling in apoptosis, two theories of the direct initiation of apoptotic mechanisms in mammals have been suggested (https://en.wikipedia.org/wiki/Fas_ligand and https://en.wikipedia.org/wiki/Apoptosis). The TNF-induced model and the Fas-Fas ligand-mediated model, both involving receptors of the TNF receptor (TNFR) family coupled to extrinsic signals. Fas ligand (FasL or CD95L) is a type II transmembrane protein that belongs to the TNF family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer, including OSCC.

The present study is a simple demonstration of the comparison of oncogenic protein expression profiles between different types of OSCCs, indicating that further investigation should be performed by examining more
cases of OSCCs using precise molecular biological methods. However, it is highly recommended that various anti-cancer drugs be developed in order to target specific oncogenic proteins in contrast to conventional chemotherapy using aggressive alkylating agents such as cisplatin, 5-fluorouracil, and methotrexate.

Conclusions
The increased trends of cellular apoptosis and invasiveness in the protein expression profile of SCC-1 implicated its extensive oral ulceration and bony destruction, while the increased trends of cellular proliferation and survival in the protein profile of SCC-2 supported its rapid growing tumor mass and early lymph node metastasis. These analyses of essential oncogenic protein expression profiles in OSCCs provide important information for genetic counseling or customized gene therapy in cancer treatment.

Acknowledgements
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI15C0689).

Funding
There is no funding related to this article.

Availability of data and materials
Protein expression profile analysis through IP-HPLC is helpful not only for the molecular genetic diagnosis of cancer but also for the determination of target molecules for customized gene therapy.

Consent for publication
Written informed consent was obtained from the patients for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Authors’ contributions
SM read and wrote the manuscript, D prepared the figures and wrote the manuscript, SK read and wrote the entire article. All authors read and approved the final manuscript.

Ethics approval and consent to participate
A statement of ethics approval in the Department of Oral Pathology at Gangneung-Wonju National University was approved by our institutional review board. This information was included in the “Methods” section.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Oral and Maxillofacial Surgery, School of Dentistry, Dental Research Institute, Seoul National University, Seoul, South Korea.
2Department of Oral Pathology, College of Dentistry, Institute of Oral Science, Gangneung-Wonju National University, Gangneung, South Korea.
3Department of Oral and Maxillofacial Surgery, College of Dentistry, Institute of Oral Science, Gangneung-Wonju National University, Gangneung, South Korea.

Received: 18 April 2017 Accepted: 22 July 2017
Published online: 08 August 2017

References
1. Lee S, Thiele C. Factors associated with free flap complications after head and neck reconstruction and the molecular basis of fibrotic tissue rearrangement in preirradiated soft tissue. J Oral Maxillofac Surg. 2010;68:2169–78.
2. Chen YW, Tu HF, Wu TH, et al. Sarcomas and sarcomatoid tumor after radiotherapy of oral squamous cell carcinoma: analysis of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:65–71.
3. Harada K, Ferdous T, Ueyama Y. Gimeracil exerts radiosensitizing effects on oral squamous cell carcinoma cells in vitro and in vivo. Anticancer Res. 2016;36:5923–30.
4. Harada K, Ferdous T, Itashiki Y, et al. Effects of cepharanthine alone and in combination with fluoropyrimidine anticanicis agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2009;29:1263–70.
5. Itashiki Y, Harada K, Ferdous T, et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2007;27:2365–75.
6. Endo H, Maramatsu T, Furuta M, et al. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis. 2013;34:560–9.
7. Kapranos N, Stathopoulos GP, Manolopoulos L, et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 2001;21:521–8.
8. Lee SS, Kim YS, Lee SK. Dysplastic proliferation of odontogenic epithelium on the xenograft bones inserted for dental implant. Kor J Oral Maxillofac Pathol. 2015;39:429–36.
9. Kim YS. Protein expression changes induced by cisplatin in an oral cancer cell line as determined by Immunoprecipitation-based high performance liquid chromatography. Korean J Oral and Maxillofacial Pathology. 2015;39:567–82.
10. Kim YS, Lee SK. IP-HPLC analysis of human salivary protein complexes. Korean J Oral Maxillofacial Pathology. 2015;39:615–22.
11. Vogeser M, Parhofer KG. Liquid chromatography tandem-mass spectrometry (LC-MS/MS)—technique and applications in endocrinology. Clin Endocrinol Diabetes. 2007;11:5559–70.
12. Hodge K, Have ST, Hutton L, Lamond AI. Cleaning up the masses: exclusion lists to reduce contamination with HPLC-MS/MS. J Proteome. 2013;88:92–103.
13. Silva SD, Cunha IW, Rangel AL, et al. Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes. Virchows Arch. 2008;453:57–67.
14. Nair S, Nayak R, Bhat K, et al. Immunohistochemical expression of CD105 and TGF-betα-1 in oral squamous cell carcinoma and adjacent apparently normal oral mucosa and its correlation with clinicopathologic features. Appl Immunohistochem Mol Morphol. 2016;24:35–41.
15. Bolt J, Vo QN, Kim WJ, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol. 2005;41:1013–20.
16. Vander Broek R, Mohan S, Eytan DF, et al. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. Oral Dis. 2015;21:815–25.
17. Nakashiro K, Tanaka H, Goda H, et al. Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma. Int J Oncol. 2015;47:1273–81.
18. Harris TM, Du P, Kawachi N, et al. Proteomic analysis of oral cavity squamous cell carcinoma specimens identifies patient outcome-associated proteins. Arch Pathol Lab Med. 2015;139:494–507.
19. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, et al. Caspase expression in oral squamous cell carcinoma. Head Neck. 2011;33:1191–8.
20. Knizevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics. 2001;1:1271–8.
21. Cui Z, Cui Y, Yang S, et al. KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/beta-catenin signaling pathway. Cell Biol Int. 2017;41:392–404.
22. Kaneko T, Zhang Z, Mantellini MG, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007;67:6885–93.
23. Zheng L, Li N, Guo F, et al. Twist-related protein 1 enhances oral tongue squamous cell carcinoma cell invasion through beta-catenin signaling. Mol Med Rep. 2015;11:2255–61.
24. Brown ME, Bear MD, Rosol TJ, et al. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res. 2015;11:206.
25. Shiah SG, Shieh YS, Chang JY. The role of Wnt signaling in squamous cell carcinoma. J Dent Res. 2016;95:129–34.
26. Lauxen IS, Oliveira MG, Rados PV, et al. Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis. 2014;20:76–80.
27. Lin X, Khalid S, Qureshi MZ, et al. VEGF mediated signaling in oral cancer. Cell Mol Biol (Noisy-le-Grand). 2016;62:64–8.
28. Erb P, Ji J, Wernli M, Kump E, Glaser A, Büchner SA. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett. 2005;15:10068–72.
29. Sugerman PB, Joseph BK, Savage NW. Review article: the role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Dis. 1995;1:172–88.
30. Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope. 2003;113:936–9.